Sage Investment Advisers LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Sage Investment Advisers LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,338 shares of the biopharmaceutical company’s stock, valued at approximately $211,000.

Other large investors also recently modified their holdings of the company. Trifecta Capital Advisors LLC increased its holdings in shares of Pfizer by 3.7% in the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 325 shares in the last quarter. Confluence Wealth Services Inc. lifted its holdings in Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after acquiring an additional 342 shares in the last quarter. Carr Financial Group Corp lifted its holdings in Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 355 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its holdings in Pfizer by 0.5% during the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after acquiring an additional 364 shares in the last quarter. Finally, Lafayette Investments Inc. boosted its position in shares of Pfizer by 2.2% during the third quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 368 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.00.

Pfizer Price Performance

Shares of PFE stock traded up $0.50 during trading hours on Wednesday, hitting $28.27. 38,868,598 shares of the company’s stock were exchanged, compared to its average volume of 43,539,004. The business’s 50 day simple moving average is $26.92 and its 200-day simple moving average is $28.12. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The company has a market capitalization of $160.08 billion, a PE ratio of -466.42, a PEG ratio of 1.17 and a beta of 0.63.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.23 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.94%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.